ALKERMES | ALKS - 资产

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.83B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	资产	更改		日
AbbVie	USD 135.12B		1.35B	2026-06
Acadia Pharmaceuticals	USD 1.74B		137.67M	2026-06
ALKERMES	USD 4.39B		135.05M	2026-06
Amgen	USD 95.64B		3.14B	2026-06
Biogen	USD 32.09B		2.6B	2026-06
BioMarin Pharmaceutical	USD 11.72B		3.13B	2026-06
Bristol-Myers Squibb	USD 87.63B		1.16B	2026-06
Coherus Biosciences	USD 191.18M		74.84M	2026-06
Eli Lilly	USD 142.28B		25.71B	2026-06
Gilead Sciences	USD 49.36B		6.92B	2026-06
Heron Therapeutics	USD 246.22M		9.66M	2026-03
Ionis Pharmaceuticals	USD 2.99B		455.5M	2026-06
J&J	USD 201.06B		167M	2026-06
Malin Corporation	EUR 198.5M		70.1M	2024-12
Merck	USD 129.8B		1.12B	2026-06
Minerva Neurosciences	USD 97.97M		69.88M	2025-12
Nektar Therapeutics	USD 763.27M		482.86M	2026-03
Neurocrine Biosciences	USD 5.36B		452.9M	2026-06
Otsuka Holdings	JPY 4.4T		186.7B	2026-06
Ovoca Bio	EUR 2.07M		414K	2025-12
Pfizer	USD 201.13B		6.49B	2026-06
Regeneron Pharmaceuticals	USD 41.73B		861.8M	2026-06
Vertex Pharmaceuticals	USD 27.42B		938.9M	2026-06